Diabetic Group (n=30), Non-diabetic Group
Conditions
Keywords
Diabetes Mellitus, cataract, aqueous humor, Del 1, IL17
Brief summary
By comparing DEL-1 and IL-17 levels in the aqueous humor of diabetic cataract patients with the aqueous humor of non-diabetic patients, we aim to understand the biochemical effects of diabetes-related inflammatory processes in the eye.
Detailed description
Developmental Endothelial Locus-1 (DEL-1) is a molecule related to endothelial cells and is a protein involved in intercellular interactions. It is generally associated with the development and function of endothelial cells lining the inner surface of the vessel. It plays an important role in the regulation of inflammation, the development of vessels and the organization of endothelial cells. It has also been shown to be associated with some types of cancer. It may also be effective in tissue regeneration and healing of injuries. IL-17 (Interleukin-17) is a group of cytokines that play an important role in the immune system. There are several subtypes of IL-17, the best known and most researched being IL-17A. It regulates the body's immune response to certain infections. It is an important cytokine that initiates and supports the inflammation process. IL-17 plays an important role in the pathogenesis of various autoimmune and inflammatory diseases. DEL-1 and IL-17 are two different molecules that act on inflammation and immune responses. DEL-1 helps regulate inflammation by protecting vascular health, while IL-17 can accelerate the course of diseases by increasing inflammation. Diabetes is a systemic disease associated with oxidative stress and chronic inflammation. Retinopathy, cataract and glaucoma diseases develop due to diabetes. DEL-1 is a protein involved in the maintenance of vascular homeostasis and regulation of inflammation. Since diabetic patients have chronic inflammation and microvascular dysfunction, changes in DEL-1 levels may provide important clues to the pathophysiology
Interventions
DIAGNOSTIC_TESTDel 1
During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. DEL 1 will be analyzed by ELISA
DIAGNOSTIC_TESTIL 17
During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. IL 17 levels will be analyzed by ELISA
Sponsors
Uşak University
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)
Masking description
During the statistical analysis, the data analyst can analyze only Group A and Group B without knowing the group names. After the results are obtained, the groups are opened.
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Cataract diagnosed and surgery planned * Patients without any other ocular pathology other than cataract. * Type 2 DM for at least 5 years in the diabetic group
Exclusion criteria
* Patients with previous intraocular surgery * Those with inflammatory eye diseases (e.g. uveitis) * Those with autoimmune diseases or systemic inflammatory diseases * Those receiving local or systemic steroid therapy * Those with severe systemic disease (e.g. advanced renal failure, malignancy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DEL-1 and IL-17 levels | Perioperative | To be measured quantitatively with ELISA kits, pg/mL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between DEL-1 and IL-17 | Perioperative | Pearson or Spearman correlation analyses will be used. pg/mL |
| Association of biomarker levels with HbA1c | Perioperative | It will be analyzed by multivariate regression analysis.mmol/mol |
| Impact of demographic factors | Baseline | The effect of age, gender and duration of diabetes on biomarkers will be statistically analyzed. Years, gender |
Countries
Turkey (Türkiye)
Contacts
Primary ContactSuzan Dogruya
Outcome results
None listed